Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Respiratory Tract Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Neoplasm Metastasis 1Liposarcoma 1Colorectal Neoplasms 1Advanced Non-small Cell Lung Cancer (NSCLC) 1Advanced Cancer 1

Interventions

Paclitaxel 4pembrolizumab 2pazopanib 2Trastuzumab 2Sorafenib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Gefitinib 2Doxorubicin 2Cisplatin 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1trametinib 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1mercaptoundecahydrododecaborate 1lenvatinib 1fosbretabulin 1efatutazone 1durvalumab 1dabrafenib 1crolibulin 1cabozantinib 1atezolizumab 1aldesleukin 1abemaciclib 1Taxes 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid Carcinoma, Anaplastic × efatutazone × Clear all
NCT02152137 2025-01-27

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
19 enrolled 13 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡